近年来AI制药兴起,全球AI制药企业超350家,国内不少于100家。3月2日,晶泰科技孵化企业ReviR宣布,其小分子药物管线RTX-117完成头例受试者给药,正式进入临床开发阶段,有望为腓骨肌萎缩症、白质消融性白质脑病等神经系统疾病患者提供治疗方案。RTX-117结合晶泰科技AI+机器人药物研发平台与ReviR对RNA生物学的理解,通过抑制异常激活的ISR通路,恢复mRNA正常翻译,从分子根源...
Source Link近年来AI制药兴起,全球AI制药企业超350家,国内不少于100家。3月2日,晶泰科技孵化企业ReviR宣布,其小分子药物管线RTX-117完成头例受试者给药,正式进入临床开发阶段,有望为腓骨肌萎缩症、白质消融性白质脑病等神经系统疾病患者提供治疗方案。RTX-117结合晶泰科技AI+机器人药物研发平台与ReviR对RNA生物学的理解,通过抑制异常激活的ISR通路,恢复mRNA正常翻译,从分子根源...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.